Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cor H J Lamers

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Cancer Immunology, Immunotherapy : CII|May 5, 2007
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivoCor H J Lamers, Sabine C L Langeveld, Corrien M Groot-van Ruijven, et al.
Thrombosis and Haemostasis|July 1, 2010
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cellsMichiel H Strijbos, Brigitte A van Krimpen, Reno Debets, et al.
Cancer|June 28, 2012
Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative studyPleun J de Raaf, Stefan Sleijfer, Cor H J Lamers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responsesJohanna E A Portielje, Cor H J Lamers, Wim H J Kruit, et al.
Blood|October 5, 2010
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cellsCor H J Lamers, Ralph Willemsen, Pascal van Elzakker, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2004
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumorsValérie Vantomme, Christine Dantinne, Noreddine Amrani, et al.
Human Gene Therapy Methods|November 26, 2014
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitnessCor H J Lamers, Sabine van Steenbergen-Langeveld, Mandy van Brakel, et al.
Blood|August 18, 2016
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantationCor H J Lamers, Rebecca Wijers, Cornelis A M van Bergen, et al.
Cytotherapy|February 8, 2013
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cellsCor H J Lamers, Pascal van Elzakker, Sabine C L van Steenbergen, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trialsJeremy L Davis, Marc R Theoret, Zhili Zheng, et al.
Cancer Immunology, Immunotherapy : CII|May 5, 2007
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivoCor H J Lamers, Sabine C L Langeveld, Corrien M Groot-van Ruijven, et al.
Thrombosis and Haemostasis|July 1, 2010
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cellsMichiel H Strijbos, Brigitte A van Krimpen, Reno Debets, et al.
Cancer|June 28, 2012
Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative studyPleun J de Raaf, Stefan Sleijfer, Cor H J Lamers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responsesJohanna E A Portielje, Cor H J Lamers, Wim H J Kruit, et al.
Blood|October 5, 2010
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cellsCor H J Lamers, Ralph Willemsen, Pascal van Elzakker, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2004
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumorsValérie Vantomme, Christine Dantinne, Noreddine Amrani, et al.
Human Gene Therapy Methods|November 26, 2014
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitnessCor H J Lamers, Sabine van Steenbergen-Langeveld, Mandy van Brakel, et al.
Blood|August 18, 2016
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantationCor H J Lamers, Rebecca Wijers, Cornelis A M van Bergen, et al.
Cytotherapy|February 8, 2013
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cellsCor H J Lamers, Pascal van Elzakker, Sabine C L van Steenbergen, et al.
Pageof 3